Brief: GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease

GB Sciences

10/04/2018 10:35

April 10 (Reuters) - GB Sciences Inc  GBLX.PK :
    * BASED THERAPY FOR PARKINSON'S DISEASE
    * EXPECTS TO COMMENCE ITS FIRST-IN-HUMAN TRIAL IN EARLY 2019
    * COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF
2018

Source text for Eikon:  urn:newsml:reuters.com:*:nCNWzMcQpa
Further company coverage:  GBLX.PK 

 ((Reuters.Briefs@thomsonreuters.com;))